Categories
US Market

Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

Sumary of Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call:

  • CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, March 24th…
  • ET to discuss full year 2020 results and provide an update on the Company recent progress and upcoming milestones…
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer…
  • The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors…
  • The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs…
  • This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995…
  • the safety and clinical activity of Celyad Oncology pipelines and financial condition, results of operation and business outlook…
  • Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements….

Want to know more click here go to source.